2025-06-12-Jefferies-重播与要点_ALKS_JAZZ_TAK关于食欲素的关键意见领袖电话会议_33页_2mb

Summary of Orexin Space Analysis from Jefferies Equity Research Report

Introduction

The report analyzes the orexin agonist space, focusing on upcoming clinical data and trial results from companies including ALKS, JAZZ, and TAK. Insights are drawn from a KOL call with Dr. Thomas E. Scammell, M.D., a neurology expert at Harvard Medical School.

• Orexin Mechanism and Dynamics: Orexin levels rise during the day and drop at night, with a baseline required for maintaining sleep quality. Orexin agonists aim to replicate this natural cycle. Tachyphylaxis mechanisms involve receptor desensitization and internalization, influenced by drug selectivity and dosing regimens.

• Efficacy Findings:

  • TAK-925 (IV): Acutely effective in narcolepsy Type 1 (NT1), but efficacy reduced with multiple dosing (44mg dose sustained in NT1; lower doses dropped despite stable concentrations).
  • TAK-861 (Ph2): Maintained efficacy for weeks 4–8 in NT1 at lower doses (2/2mg and 2/5mg), with KOL noting no significant waning for biphasic regimens. In NT2, suboptimal dosing may explain reduced MWT efficacy (2/2mg and 2/5mg; wide error bars). KOL emphasized the need for data across patient populations (NT1, NT2, IH) to confirm sustained effects.

• Patient Population Variations:

  • NT1: Higher sensitivity at lower orexin doses due to deficiency-induced receptor upregulation. KOL bullish on NT1 prospects but cautious for NT2 and IH where baseline orexin levels are normal, and trials may involve underdosing.
  • Tachyphylaxis Risk: Uncertain in NT2/IH populations; could depend on receptor saturation (normal orexins in NT2/IH) vs. sensitivity in NT1. KOL suggested increasing doses or optimizing PK profiles to counteract potential loss of efficacy.

• Safety Profile:

  • On-Target Adverse Events (AEs): Visual disturbances are attributed to orexin OX1R-mediated pupillary changes; insomnia and urgency are common but mild and transient. Preclinical data on TAK-994 raised liver toxicity concerns at higher doses, but next-gen agonists (e.g., <25mg) may mitigate risks. Overall AE rates low in trials, with flat trough levels showing promise.
  • β-Arrestin Role: GPCR internalization dynamics (e.g., OX2R slower recycling) influence tachyphylaxis and bias in signaling; studies highlight receptor desensitization mechanisms.

• Market and Label Expansion:

  • Market Opportunity: Potential for >60% market share in NT1 if efficacy holds, with payer challenges due to high costs. Sodium oxybate may persist alongside orexin agonists in real-world use, targeting subjective sleep quality.
  • Broader Applications: Preclinical data suggest potential for ADHD, major depressive disorder (MDD), and other conditions via orexin's cognitive and arousal effects. KOL is more cautious on Alzheimer's and less bullish on off-label use for payer-restricted conditions.

• Conclusion: Orexin agonists show promise for NT1, with ongoing trials providing mixed efficacy data on tachyphylaxis. Companies like ALKS and TAK are key players, pending more data on sustained effects, safety margins, and market penetration.